About Me
Dr. Weintraub's approach emphasizes collaboration and tailored treatment plans, ensuring patients receive the best possible care suited to their unique needs. He specializes in managing patients with a wide range of endocrine conditions, including obesity, diabetes, osteoporosis, and disorders of the thyroid, adrenal, and pituitary.
His particular interest lies in obesity medicine, a dynamic field that offers increasingly effective tools for treating and preventing weight gain, which is often the root cause of many chronic diseases. By working closely with nutritionists, surgeons, and other specialists, he strives to deliver holistic and effective care.
In addition to caring for patients, Dr. Weintraub is passionate about academic medicine, research, and training the next generation of physicians. He co-chairs the pharmacologic management of obesity guideline update through the Endocrine Society and serves on the exam writing committee for the American Board of Obesity Medicine. He is actively involved in clinical research within endocrinology and obesity medicine.
Academic & Professional Contributions
NEJM Course Faculty Director
Faculty Director for the New England Journal of Medicine Group's "Advancing Obesity Care" course, collaborating with leading experts to deliver evidence-based approaches for obesity management and GLP-1 therapies.
Learn More
Endocrine Society Guidelines Co-Chair
Co-Chair of the pharmacologic management of obesity guideline update through the Endocrine Society, leading the development of evidence-based recommendations for obesity pharmacotherapy.
Learn More
American Board of Obesity Medicine
Serving on the exam writing committee for the American Board of Obesity Medicine, contributing to the certification and education of obesity medicine specialists nationwide.
Learn MoreEndocrine News Podcast
Featured expert discussing compounded obesity medications, addressing regulatory considerations, safety, efficacy, and patient access concerns in the evolving landscape of obesity pharmacotherapy.
Listen Now
DocWire News: EASO Framework Discussion
Expert commentary on how the European Association for the Study of Obesity framework reshapes clinical practice by moving beyond BMI to focus on individualized, health-centered approaches.
Watch Video
Medscape: GLP-1 Discontinuation Research
Discussing real-world data presented at ObesityWeek on weight regain patterns after GLP-1 discontinuation and implications for long-term obesity management strategies.
Read Article
ObesityWeek 2025
Presented real-world evidence on weight regain after GLP-1 discontinuation, highlighting the chronic nature of obesity and the importance of continuous treatment strategies.
View Details
2026 Columbia Cornell Obesity Medicine Course
Lecturer for the Columbia Cornell intensive CME program covering evidence-based approaches to obesity etiology, prevention, and treatment. Course emphasizes practical pharmacologic, nutritional, behavioral, and procedural interventions for patient-centered care.
Course InformationEndocrine Society Obesity Fellows Program Keynote
Recurring keynote speaker (2023, 2024, 2025) for the Endocrine Society’s Obesity Fellows Program, delivering the annual lecture on the state of obesity medicine to fellows training in the field nationwide.
Learn MoreAvailable for CME courses, grand rounds, and media interviews.
Request Speaking EngagementEducation and Training
-
Fellowship — Endocrinology, Diabetes & Metabolism
Cornell NewYork-Presbyterian HospitalMemorial Sloan Kettering Cancer Center -
Residency — Internal Medicine
Thomas Jefferson University Hospital -
Medical School
Rutgers Robert Wood Johnson Medical School -
Undergraduate
University of PennsylvaniaThe Wharton School
Practice Location
NYU Langone Diabetes & Endocrine Associates
222 East 41st Street, 23rd Floor
New York, NY 10017
Select Publications
Defining disease or delaying care? A conceptual and clinical appraisal of the Lancet obesity framework
Five-year weight loss maintenance with obesity pharmacotherapy
GLP-1 Receptor Agonist Outcomes, Safety, and Body Mass Index Change in a National Cohort of Patients on Dialysis
GLP-1 Receptor Agonists in Kidney Transplant Recipients with Pre-Existing Diabetes: A Retrospective Cohort Study
Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition
Recent Commentary
I actively share research insights, clinical commentary, and updates on obesity medicine and GLP-1 therapies across professional platforms.
TRIUMPH-1: Retatrutide Phase 3 Obesity Data
Live coverage from ADA 2026 of the TRIUMPH-1 Phase 3 trial of retatrutide, a once-weekly triple hormone receptor agonist. At 80 weeks and 12 mg, participants achieved 28.3% average body weight reduction (70.3 lbs), with more than 1 in 4 losing at least 35%. Health outcomes included over 70% reduction in WOMAC knee pain, over 60% reduction in apnea-hypopnea index for OSA, and reversion to normoglycemia in more than 95% of those with prediabetes.
View Thread
A1c Reduction: Semaglutide vs. Tirzepatide vs. Retatrutide
An indirect comparison of HbA1c reduction across the SUSTAIN-1, SURPASS-1, and TRANSCEND-T2D-1 Phase 3 studies. Retatrutide and tirzepatide produced comparable A1c reductions — evidence that adding glucagon agonism does not raise glucose, countering a common concern about triple-agonist therapy.
Read Full Post
Survodutide and Liver Fat: A Striking MRI Case
"Now you see it, now you don't." A SYNCHRONIZE-MASLD MRI-PDFF case study showing liver fat content falling from 35% to 2% after 48 weeks of survodutide, a dual GLP-1/glucagon receptor agonist that demonstrated 16.6% weight loss at 76 weeks in its Phase 3 program.
View Thread
Peptides With Real Evidence vs. The Hype
GLP-1 is just one of several nutrient-stimulated hormones with real human-trial data behind them. This post flags where the clinical evidence actually exists — amylin, GIP and glucagon agonism — and cautions against the rapidly growing market of peptides sold online without supporting trials or oversight.
Read Full Post
Follow for Regular Updates
Join me for regular insights on obesity medicine, GLP-1 research, and endocrinology